PharmaEssentia
MA - BurlingtonBiotechnology
Focus: PharmaEssentia is a Massachusetts-based biotech founded in 2003 specializing in biologic therapeutics for hematology, oncology, infectious diseases, and immunology. The company is heavily dependent on its single approved product, BESREMI (ropeginterferon alfa-2b), which generates 100% of revenue.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Open Jobs
0
About PharmaEssentia
AI assessmentNot HiringNo open roles listed right now. Follow PharmaEssentia to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from PharmaEssentia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$40M Part DStable
Peak
Only approved and revenue-generating product; JAK-independent interferon-based therapy addressing unmet need in polycythemia vera treatment.
Products & Portfolio (1)
Help build intelligence for PharmaEssentia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.